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Abstract: The ultimate success of in vivo organ formation uti-
lizing ex vivo expanded ‘‘starter’’ tissues relies heavily upon
the level of vascularization provided by either endogenous or
artiﬁcial induction of angiogenic or vasculogenic events. To
facilitate proangiogenic outcomes and promote tissue
growth, an elastomeric scaffold previously shown to be
instrumental in the urinary bladder regenerative process was
modiﬁed to release proangiogenic growth factors. Carboxylic
acid groups on poly(1,8-octanediol-co-citrate) ﬁlms (POCfs)
were modiﬁed with heparan sulfate creating a heparan bind-
ing POCf (HBPOCf). Release of proangiogenic growth factors
vascular endothelial growth factor (VEGF), ﬁbroblast growth
factor 2 (FGF2), and insulin-like growth factor 1 (IGF-1) from
HBPOCfs demonstrated an approximate threefold increase
over controls during a 30-day time course in vitro. Atomic
force microscopy demonstrated signiﬁcant topological differ-
ences between ﬁlms. Subcutaneous implantation of POCf
alone, HBPOCf, POCf-VEGF, and HBPOCf-VEGF within the
dorsa of nude rats yielded increased vascular growth in
HBPOCf-VEGF constructs. Vessel quantiﬁcation studies
revealed that POCfs alone contained 41.1 6 4.1 vessels/mm2,
while HBPOCf, POCf-VEGF, and HBPOCF-VEGF contained
41.7 6 2.6, 76.3 6 9.4, and 167.72 6 15.3 vessels/mm2,
respectively. Presence of increased vessel growth was dem-
onstrated by CD31 and vWF immunostaining in HBPOCf-
VEGF implanted areas. Data demonstrate that elastomeric
POCfs can be chemically modiﬁed and possess the ability to
promote angiogenesis in vivo. VC 2011 Wiley Periodicals, Inc.
J Biomed Mater Res Part A: 100A: 561–570, 2012.
Key Words: angiogenesis, elastomer, localization, growth fac-
tor, blood vessel
How to cite this article: Sharma AK, Bury MI, Fuller NJ, Rozkiewicz DI, Hota PV, Kollhoff DM, Webber MJ, Tapaskar N, Meisner JW,
Lariviere PJ, DeStefano S, Wang D, Ameer GA, Cheng EY. 2012. Growth factor release from a chemically modiﬁed elastomeric
poly(1,8-octanediol-co-citrate) thin ﬁlm promotes angiogenesis in vivo. J Biomed Mater Res Part A 2012:100A:561–570.
INTRODUCTION
Organogenesis embodies a number of highly interdependent
physiological events that must be properly coordinated to
establish an anatomically correct and physiologically func-
tional organ. Regenerative medicine-based strategies
attempt to closely mimic these processes so that organ
replacement therapies may eventually become a reality.
Within the realm of urinary bladder regenerative medicine,
many of these requirements have gone unfulﬁlled. Instances
in which patients are undergoing corrective surgical proce-
dures to repair urinary bladder defects such as those found
in spina biﬁda associated neurogenic bladder often demon-
strate short- and long-term side effects.1 Although attempts
have been made to create a physiologically functional uri-
nary bladder, only partial regeneration in the forms of uri-
nary bladder constituents such as muscle and urothelial tis-
sues has been achieved.2 This is also often accompanied by
a marginal vascular supply within the core of the grafted
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area that may contribute to increased scar formation, thus
decreasing bladder contractile/expansion potential.3,4 The
angiogenic process in implanted bladder tissue that has
been used as a ‘‘patch’’ during bladder augmentation proce-
dures is typically limited in its ability to create complex
interconnected vascular networks and is characterized by
poor vessel integrity unless omentum is applied to the aug-
mented tissue.5 Furthermore, a robust vasculogenic process
involved with complete bladder replacement procedures has
yet to be demonstrated. Hence, a method in which to
enhance angiogenic events would be highly desirable in a
bladder regenerative milieu.
Several proangiogenic growth factors contain internal
amino acid sequences that allow for coupling to motifs found
in naturally occurring molecules. The Cardin–Weintraub con-
sensus amino acid sequence and other amino acid sequences
possess heparin binding domains found in growth factors
such as vascular endothelial growth factor (VEGF) and mem-
bers of the ﬁbroblast growth factor (FGF) family that favor
efﬁcient binding to molecules of heparin.6–8 This in turn pro-
vides a potential vehicle of proangiogenic growth factor deliv-
ery for in vivo applications. The extended release of growth
factors in localized areas of implanted scaffold/cell compo-
sites would provide an invaluable pillar for further tissue
growth as localized growth factor delivery to enhance vascu-
lar development, and maturation has been proven to be ad-
vantageous in a number of in vivo settings.9,10
Scaffold choice is critical in the urinary bladder regenera-
tive process, since it should be able to mimic and withstand
repeated cycles of mechanical strain without permanent de-
formation or loss of tensile strength. Dahms et al. describe
various mechanical testing parameters of the human bladder
and reveal that it possesses an elastic modulus of 250
kPa.11 The family of poly(diol citrates) has demonstrated its
abilities to function within tissues with high elastomeric
requirements.12,13 We have recently demonstrated the utility
of the elastomeric scaffold poly(1,8-octanediol-co-citrate)
(POC) in the context of urinary bladder regeneration.14 This
study demonstrated the feasibility of mesenchymal stem cell
(MSC) seeded POC scaffolds and their ability to regenerate
the muscle component of the bladder wall in an established
bladder augmentation model. The contractile/expansive me-
chanical forces endured by the POC/MSC composite helped
propel the regenerative process as it has been demonstrated
that scaffold mechanical stimulation promotes tissue regener-
ation.15 To ultimately facilitate the regenerative processes
involved with urinary bladder regeneration, we have created
a chemically modiﬁed heparan binding POC ﬁlm (HBPOCf)
with the potential to release proangiogenic growth factors in
an in vivo environment and promote localized vascular
growth as a proof of concept study.
MATERIALS AND METHODS
HBPOCf synthesis and growth factor loading
POCfs were prepared as previously described.12–14 HBPOCfs
were created by activating the carboxylic acid groups found
on POCfs in 10-mL MES buffer [2-(N-morpholino)ethanesul-
fonic acid] pH 6.0, containing 0.15-g 1-ethyl-3-(3-dimethyla-
minopropyl) carbodiimide hydrochloride (EDC) and 0.09-g
N-Hydroxysuccinimide (NHS) for 2 h at room temperature
with agitation. Films were subsequently rinsed three times
in water and incubated in 10-mL MES buffer pH 6.0, con-
taining 75-mg PEG-diamine (MW 2000) for 12 h at room
temperature with agitation. Films were then rinsed three
times with water. Heparan sulfate (Celsus Laboratories, Cin-
cinnati, OH) was activated by adding 0.4-g EDC and 0.097-g
NHS to a 1% solution of heparan sulfate in 50 mL of MES
buffer pH 6.0 for 1 h at room temperature. POCfs were
incubated in the activated heparan sulfate solution for 4 h
at room temperature under agitation. Films were rinsed
three times in water and stored in Dulbecco’s Phosphate
Buffered Saline (DPBS, BioWhittaker, Walkersville, MD). A
toluidine blue assay was performed to determine the
amount of heparan bound to HBPOCfs. A 0.5 mL of toluidine
blue solution (0.005% toluidine blue in 0.01M HCl with
0.2% NaCl) was added to a 15-mL tube. Subsequently, 1 mL
of 0.2% NaCl and the HBPOCfs were added to the tube and
vortexed for 30 s. A 1 mL of hexane was added to the mix-
ture followed by another 30 s of vortexing. 100–200 lL
samples of the aqueous layer was removed and placed in a
96-well plate and read at 631-nm absorbance using a Spec-
tramax M5 Plate Reader (Molecular Devices, Sunnyvale, CA).
Mechanical testing of POCfs
Tensile mechanical tests were conducted using an Instron
5544 mechanical tester (Instron, Grove City, PA) equipped
with a 500N load cell. Dog bone shaped samples of POCfs
(5.0 cm  1.0 cm) were pulled at a rate of 500 mm/min,
and the Young’s modulus of the POCfs was determined by a
regression of the linear portion (slope) of the tensile stress/
strain data calculated using the sum of least squares
method in Excel 2007 (Microsoft Corporation, Redmond,
WA).14 Data are represented as means 6 95% conﬁdence
intervals.
Atomic force microscopy
Tapping mode atomic force microscopy (TM-AFM) was per-
formed with a Dimension ICON P scanning probe micro-
scope (Veeco, Plainview, NY). The probe was composed of
silicon with an aluminum reﬂex coating, with a spring con-
stant of 42 N/m, a resonant frequency of 300 (200–400)
kHz, and a tip radius of 9 6 2 nm (Asylum Research, Santa
Barbara, CA). Image analysis was performed with Nano-
Scope Analysis version 1.2 software. After scanning, the
images were subjected to ﬁrst-order plane ﬁtting and ﬂat-
tening to remove curvature and slope. The average surface
roughness (Ra) was calculated on a 2.56 lm
2 area (1.6 lm
 1.6 lm) of each sample and was obtained from a mini-
mum of three separate images acquired from different
regions of the POCf, POCf-VEGF, or HBPOCf-VEGF samples.
All analyses were conducted on dry, cleaned samples at
room temperature in an atmosphere with 30% relative
humidity.16
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Growth factor loading and release quantiﬁcation from
POCfs
The human growth factors vascular growth factor (VEGF),
ﬁbroblast growth factor 2 (FGF2), and insulin-like growth
factor 1 (IGF-1) (100 ng/mL POCf each in vitro or 300 ng/
scaffold in vivo; R and D Systems, Minneapolis, MN) were
individually mixed into a DPBS solution containing 0.1% bo-
vine serum albumin [BSA (release media), Sigma Aldrich, St.
Louis, MO] by manual pipetting. About 500 lL of this solu-
tion was added to half-moon cutouts of POCfs, HBPOCfs, or
HBPOCfs-VEGF and placed in individual 1-mL Eppendorf
tubes for 3 h at room temperature with gentle agitation.
Half-moon cutouts were 5 mm in diameter and 2.5 mm in
width. The thicknesses of the ﬁlms were as follows: POCf (n
¼ 10) 0.24 6 0.05 mm (SD); HBPOCf (n ¼ 10) 0.25 6 0.05
mm (SD); and HBPOCf-VEGF (n ¼ 10) 0.24 6 0.06 mm
(SD). Subsequently, the ﬁlms were removed and washed
three times with 200 lL of DPBS and placed in a 48-well
plate (Corning Life Sciences, Lowell, MA). Samples were
placed in a 37C incubator with 5% CO2 in air and collected
on days 1–6 and then on days 9, 11, 13, 15, 20, 25, and 30
by removing 200 lL of conditioned release media and
replacing with 200 lL of fresh release media. Samples then
underwent growth factor quantiﬁcation with the appropri-
ate enzyme-linked immunosorbent assay (ELISA) Assay (R
and D Systems) for the detection of the aforementioned
human growth factors, as previously described.17–19 The
supernatants were brieﬂy centrifuged and placed in their
respective ELISAs and assayed according to manufacturer’s
instructions. Samples were run in triplicate for each growth
factor at each time point. Absorbance was read using the
Spectramax M5 Plate Reader at wavelengths of 450 and 540
nm. Data represented as amount of growth factor (pg)
released relative to the total surface area of the scaffold
(22.58 mm2).
Subcutaneous implantation of growth factor containing
POCfs
Adult athymic female nude rats (NCI Animal Production Pro-
gram, Frederick, MD) weighing 200–250 g underwent sub-
cutaneous scaffold implantation as previously described.20
Animals were anesthetized with 60-mg/kg ketamine and 5-
mg/kg xylazine intraperitoneally and given an analgesic injec-
tion of Buprenex (1 mg/kg) administered subcutaneously to
decrease any pain during and after surgery. Three 0.5-cm
incisions were made on the right, dorsal aspect of the animal
within the thoracic and lumbar regions of the back. The
quadrant of dorsum used for each scaffold implantation was
rotated for each successive animal, to control for any effects
of the implant site. The incisions were widened to accommo-
date POCfs or HBPOCfs (1.0-cm diameter), which were
implanted into the subcutaneous layer of the dorsum of the
animal. Incisions were closed with 9-mm autoclips, and a
topical triple antibiotic ointment was applied to incision
areas. This procedure was repeated on the contralateral side
of the animal for a total of six implanted scaffolds per animal
(n ¼ 3–5 total animals). Animals were sacriﬁced at 4 weeks
post-implantation. Full thickness tissue sections from the
skin to the muscle were dissected and prepared for histologi-
cal analyses. All pre- and post-animal procedures were per-
formed in accordance with guidelines set forth and approved
by the Children’s Memorial Hospital Institutional Animal Care
and Use Committee (IACUC). NIH guidelines for the care and
use of laboratory animals (NIH Publication #85-23 Rev.
1985) have been observed.
Masson’s Trichrome staining of implanted HBPOCfs
Subcutaneous tissue specimens were isolated immediately
following euthanasia and were ﬁxed in 10% buffered forma-
lin phosphate (Fisher Scientiﬁc, Pittsburgh, PA) and dehy-
drated through a series of graded ethanol exchanges then
embedded in parafﬁn. Embedded tissues were sectioned
onto glass slides at a thickness of 5–15 lm using a RM2125
RT Microtome (Leica, Nannockburn, IL) and subjected to
Masson’s Trichrome (Sigma-Aldrich) staining as previously
described.14 Following de-parafﬁnization, slides were placed
in Bouin’s solution for 15 min, then rinsed under running
tap water, and followed by Hematoxylin and Scarlet-Acid
Fuchsin staining for 5 min sequentially. Following a rinse
with deionized water, slides were subjected to a mixture of
PTA/PMA, followed by Aniline Blue solution, and a 1% ace-
tic acid wash. Finally, slides were placed in 95%–100%
ethanol and rinsed in xylene. After drying, a coverslip was
placed over the tissue and secured with 3–4 drops of Per-
maslip (Alban Scientiﬁc, St Louis, MO).
Immunoﬂuorescent characterization of subcutaneously
implanted tissues
Slides containing sectioned tissue samples were subjected
to antigen retrieval consisting of 15 min of boiling in citrate
buffer (0.01M citrate solution, pH 6.0 with 0.05% Tween-
20) and then cooled to room temperature. Staining con-
sisted of a blocking step for 15 min in BSA (5 mg/mL) fol-
lowed by a 40-min incubation at room temperature with
the primary antibody. After washing with DPBS, slides were
incubated for 30 min with a secondary antibody and even-
tually rinsed with DPBS and air dried. Slides were mounted
with Vectashield (Vector Laboratories, Burlingame, CA). The
primary antibodies used in this study were directed against
epitopes of known endothelial cell origin including PECAM
(CD31) and von Willebrand Factor (vWF; Santa Cruz Bio-
tech, Santa Cruz, CA).21 Antibodies were either directly con-
jugated to ﬂuorescein isothiocyanate (FITC) or used in con-
junction with a FITC conjugated secondary antibody
(Molecular Probes, Carlsbad, CA) following established pro-
tocols.13 Primary antibodies were used at dilutions ranging
from 1:100 to 1:250, and the secondary antibody was used
at a 1:400 dilution. Samples were additionally stained with
40,6-diamidino-2-phenylindole (DAPI) to identify cell nuclei.
In vivo vessel density quantiﬁcation
Trichrome images were characterized using a Nikon Eclipse
50i Microscope (Nikon, Melville, NY) and Spot Advanced
Imaging Software (Diagnostic Instruments, Sterling Heights,
MI). Sample images (1600 pixels  2000 pixels, bit depth 24)
were opened with Adobe Photoshop CS3 (Adobe Systems, San
ORIGINAL ARTICLE
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A | MAR 2012 VOL 100A, ISSUE 3 563
Jose, CA). Images (n ¼ 12) were taken from each implant and
extended across the entire length of the implant with a total
imaged area of 0.79 mm2. The number of vessels was quanti-
ﬁed using the pen tool by way of the shape tools setting. Indi-
vidual vessels were selected manually and subsequently quan-
tiﬁed using the image histogram tool to acquire pixel density
for each vessel. Data represented as mean number of vessels
per mm2, 695% conﬁdence intervals.
Statistical analyses
Growth factor release data are represented as raw data
points with ﬁtted lines and 95% predictive intervals. Poly-
nomial regression in a linear mixed model was used to ﬁt
data values over time. Comparisons between different con-
structs were considered at each time point. p-values were
adjusted with the Tukey–Kramer method for multiple com-
parisons; adjusted p-values of <0.05 were considered signif-
icant. Implant data are shown as mean 6 95% conﬁdence
intervals. Differences between control (nonmanipulated ani-
mals), POCf, HBPOCf, POCf-VEGF, and HBPOCf-VEGF implant
groups, with respect to the number of vessels, were ana-
lyzed using a linear mixed model, with the Tukey–Kramer
adjustment for multiple comparisons; adjusted p-values of
<0.05 were considered signiﬁcant. Analyses were per-
formed with SAS 9.2 software (SAS Institute, Cary, NC).
Release data plots were generated using R Software (The R
Foundation for Statistical Computing, www.r-project.org).
RESULTS
POCf mechanical characteristics
Synthesized POCfs, HBPOCfs, and HBPOCfs-VEGF were eval-
uated for their stiffness by undergoing tensile mechanical
stress evaluation (Fig. 1). The Young’s modulus for standard
POCfs was calculated to be 0.925 6 0.173 MPa (n ¼ 12) in
comparison with 0.806 6 0.010 MPa (n ¼ 12) for the
HBPOCfs and 0.752 6 0.097 MPa (n ¼ 13) for the
HBPOCfs-VEGF. The mechanical data suggest that modiﬁca-
tion of POC ﬁlms with either heparan sulfate and/or VEGF
does not signiﬁcantly alter the elasticity of the ﬁlm. Further
mechanical testing data demonstrated an elongation at
break (Eb) of 304.61% 6 1.77%, 306.52% 6 2.36%, and
305.91% 6 1.67% for POCf, HBPOCf, and HBPOCf-VEGF,
respectively. The elongation break is deﬁned as the percent-
age of the original length of the elastomer at breaking point.
All groups of POCfs retained their elastic potential and plia-
bility when manipulated. Furthermore, permanent deforma-
tion after stretching was not observed.
Atomic force microscopy measurements
Surface morphology of POCfs, HBPOCfs, and HBPOCfs-VEGF
was investigated using TM-AFM in air. All groups of POCfs
displayed textured surface morphology with a typical fea-
ture size of 50–300 nm. Figure 2 contains representative
AFM height images and cross-sectional analyses of POCfs,
HBPOCfs, and HBPOCfs-VEGF. The most uniform surface
asperity coverage was found in HBPOCf-VEGF, where the
average asperity size was 130 6 20 nm. Average surface
roughness (Ra) is the most commonly used roughness
measurement.22 This represents the arithmetic average of
the absolute values of the surface height deviations meas-
ured from the mean plane and is expressed as
Ra ¼ 1N
XN
j¼1
jZjj
where N is the number of points, Z is the difference
between height and mean plane in the image, and Zj is the
current Z value. The Ra was calculated as 4.8 6 0.3 nm for
POCf, 5.5 6 0.7 nm for HBPOCf, and 8.6 6 2.0 nm for
HBPOCf-VEGF. The surface morphology of POCf and POCf-
VEGF was comparable with close Ra values. HBPOCf-VEGF
showed the most distinct surface characteristics with the
highest Ra values as the surface appears to have the most
textured morphology (Fig. 2).
Heparan sulfate binding and in vitro growth factor
release quantiﬁcation
Quantiﬁcation of heparan sulfate binding to POCfs resulted in
an average of 6.03 6 1.77 lg/mL of heparan bound to POCfs.
POCf and HBPOCf constructs were assessed with regard to
growth factor loading. HBPOCf constructs showed threefold
to ﬁvefold higher levels (VEGF and IGF-1 3 greater; FGF2
5 greater). Loading levels were greatest for IGF-1 (POCf
34.1 6 9.5; HBPOCf 116.7 6 3.7), pg of GF/mm2 POC for all
FIGURE 1. Mechanical testing data of POCfs. The modulus of each
POCf was determined from the derivation of the Young’s modulus
(YM). (A) POCfs demonstrated a YM of 0.925 6 0.173 MPa. (B)
HBPOCfs possessed a YM of 0.806 6 0.010 MPa. (C) HBPOCfs-VEGF
maintained a YM of 0.752 6 0.010 MPa.
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conditions, at approximately twice the levels of VEGF (POCf
17.3 6 0.4; HBPOCf 53.8 6 5.3) and six and four times the
amount of FGF2 (POCf 5.3 6 2.2; HBPOCf 28.2 6 5.0). In
terms of the GF available for loading, these quantities repre-
sent 1.05% 6 0.30% and 3.50% 6 0.14% (IGF-1; POCf,
HBPOCf), 0.41% 6 0.02% and 1.28% 6 0.11% (VEGF; POCf,
HBPOCf), and 0.14% 6 0.08% and 0.75% 6 0.14% (FGF2;
POCf, HBPOCf), respectively. Release of VEGF, IGF-1, and
FGF2 from POCf and HBPOCf constructs was monitored over
a 30-day period. POCf and HBPOCf constructs were compared
for each growth factor tested. In each group comparison,
HBPOCf constructs released signiﬁcantly greater levels of
growth factor at all time points after day 1 (p < 0.05 POCf-
FGF2 vs. HBPOCf-FGF2 at day 2; p < 0.0001, all other com-
parisons). At 30 days, IGF-1 release amounts were 87.0 6
3.1 HBPOCf versus 25.0 6 1.7 POCf (pg of GF/mm2 POC for
all conditions) [Fig. 3(A)], while VEGF release amounts were
12.9 6 1.8 HBPOCf versus 4.7 6 0.9 POCf [Fig. 3(B)]. Finally,
FGF2 release amounts were 4.8 6 0.6 HBPOCf versus 1.3 6
0.1 POCf [Fig. 3(C)]. Data are represented here as mean 6
95% conﬁdence intervals. Growth factor conjugated HBPOCfs
demonstrated an initial release of 20% of the total at day 1
(range 21%–25%), increasing to 50% at day 4 and 75%
by day 9. Release was slightly accelerated for POCf-VEGF and
POCf-IGF1, with day 1 values at 28%–30% total release,
increasing to 50% at day 3 and 75% by day 6. The POCf-
FGF2 construct followed a slower course, beginning with a
lower day 1 value of 10% total release and reaching 50%
(D5) and 75% (D11). Construct comparison trends (POCf
vs. HBPOCf; IGF-1 vs. VEGF vs. FGF2) for release data were
consistent with trends observed in loading data [Fig. 3(D)].
Histological evaluation of subcutaneously implanted
POCfs
As implanted ﬁlms were removed from rat backsides 4 weeks
post-implantation, it was observed that the ﬁlms had inte-
grated completely into the local environment. Full thickness
subcutaneous samples (consisting of skin to the muscle base)
were removed and evaluated. Upon extraction of tissue/POCf
composites, it was immediately obvious that signiﬁcant differ-
ences in vascularity were apparent with regards to each POCf
type by gross examination. Figure 4(A,E) depicts gross images
of nonmanipulated POCfs, and they appear to have a lack of
vascular distribution at the macroscopic level. Figure 4(B,F)
depicts HBPOCf implants that demonstrate very low levels of
vascularity. Figure 4(C,G) shows POCf-VEGF stimulated tissue
and there appears to be low levels of vascular growth as indi-
cated by the black arrows. In contrast, Figure 4(D,H) shows
the HBPOCf-VEGF construct demonstrate robust vascular
growth, again depicted by the black arrows, in what appears
to be a localized area. Data in this image are representative of
two animals, but the levels of vascular growth were consistent
in all animals. Histological analyses in the form of Trichrome
staining of the aforementioned constructs appear to corrobo-
rate gross ﬁndings as represented in Figure 5. Figure 5(A,F)
shows tissue from a control animal that did not receive any
scaffold implantation (denoted as Control in ﬁgures). Figure
5(B,G) contains tissue with the POCf and shows very little evi-
dence of vascularization and is similar to untreated control
samples. HBPOCf [Fig. 5(C,H)] shows sparse vessel formation.
POCf-VEGF tissue containing constructs [Fig. 5(D,I)] shows
slightly higher levels of vessel growth with apparent sporadic
distribution. Vessels generally appear larger in diameter than
POC alone samples and retain small quantities of red blood
cells within the lumen of the vessel. The HBPOCf-VEGF con-
structs seen in Figure 5(E,J) show the greatest difference in
vessel number and size. Findings were consistent throughout
all animals. Figures represent dorsal tissue taken from two
separate animals. Green arrows indicate blood vessels (400
mag; scale bar ¼ 50 lm).
Immunoﬂuorescent staining of in vivo derived
POCf/tissue composites
To verify that the structures in implanted regions were
indeed blood vessels, immunostaining with two well estab-
lished endothelial cell markers (CD31 and vWF) was used,
FIGURE 2. Atomic force microscopy measurements. TM-AFM three-dimensional height images of surface topography of (A) POCfs, (B)
HBPOCfs, and (C) HBPOCfs-VEGF, and their cross-sectional analyses. Data indicate that average roughness (Ra) was greater in HBPOCfs-VEGF
compared with controls. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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as blood vessels are composed of a single layer of endothe-
lial cells.21 Figure 6(A,F) represents control sample tissue,
while Figure 6(B,G) is POCf tissue samples stained with
CD31 and vWF, respectively. Data demonstrate scant vascu-
larization in these areas. HBPOCf implanted samples [Fig.
6(C,H)] are similar in vessel representation as the control
and POCf samples. POCf-VEGF containing samples are simi-
larly stained in Figure 6(D,I) and show an increase level in
vasculature in the implanted area. Finally, Figure 6(E,J) dem-
onstrates the biggest increase in vessel density and size
with positive staining for both endothelial cell markers. Im-
munoﬂuorescent data suggest that vascular levels were sig-
niﬁcantly higher in HBPOCf-VEGF constructs than controls.
Data were consistent in all animals and further corrobo-
rated by vessel quantiﬁcation studies performed in the next
subsection. The apparent yellow ﬂuorescence found within
the lumen of blood vessels is due to red blood cell auto-
ﬂuorescence [most apparent in Fig. 6(D)] (400 mag; scale
bar ¼ 50 lm).
Vasculature quantiﬁcation in implanted areas
HBPOCf-VEGF implants produced a signiﬁcantly enhanced
vascular response in the surrounding tissue as compared
with POCfs, HBPOCfs, and POCfs-VEGF. The addition of hep-
aran conjugated VEGF resulted in approximately four times
the response observed with POCf or HBPOCf alone and
approximately two times the response seen with the addi-
tion of free VEGF. Speciﬁcally, mean values (n ¼ 10–11
implants per condition) were 41.1 6 4.1 vessels/mm2
region for the POCf group, 41.7 6 2.6 vessels/mm2 for the
HBPOCf group, 76.3 6 9.4 vessels/mm2 for the POCf-VEGF
group, and 167.7 6 15.3 vessels/mm2 for the HBPOCf-VEGF
FIGURE 3. In Vitro growth factor release analyses. (A) IGF-1 constructs showed the highest levels of growth factor release, followed by VEGF
constructs (B), with FGF2 constructs releasing the lowest levels (C), and (D) demonstrates HBPOCf constructs released signiﬁcantly higher levels
of growth factors than POCf constructs. Data shown as raw data points with ﬁtted lines and 95% predictive intervals (*p < 0.05 POCf-FGF2 vs.
HBPOCf-FGF2 at day 2; *p < 0.0001 all other comparisons). [Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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group (n ¼ 5 animals) (Fig. 7). Nonimplant control samples
displayed 38.8 6 6.1 vessels/mm2 were similar to POCf and
HBPOCf control samples. Thus, the increased vascular
response conferred by addition of free VEGF is further
enhanced by VEGF presented in the heparan-binding
construct.
DISCUSSION
The biological processes by which an organ undergoes
regeneration in vivo are inﬂuenced by numerous environ-
mental parameters. These include cell–interface interactions
along with cellular modulation by soluble and nonsoluble
factors, which may be autocrine or paracrine in nature that
modulate re-cellularization, cell migration, and growth.23,24
Dimensionality and mechanical stimulation also play signiﬁ-
cant roles in the formation and differentiation of cell-
derived tissues since the native states of regenerative proc-
esses occur in three dimensions, hence choice of a scaffold
and its mechanical properties are crucial for proper organ
formation for regenerative purposes.15,25 In the ﬁeld of uro-
logical tissue engineering, great strides have been made
over the last several years to create replacement structures
FIGURE 4. Macroscopic analyses of 4-week POCf implanted tissue specimens: (A,E) depict subcutaneously implanted POCfs removed from the
dorsal area of a nude rat, Note the scarcity of blood vessels, (B,F) depict implanted HBPOCfs, and (C,G) are similar conditions but implanted
with POCfs-VEGF. The level of vascularity increases with the addition nonchemically conjugated VEGF. (D,H) shows the highest levels of local-
ized vascularization using the HBPOCfs-VEGF subcutaneously implanted as indicated by the black arrows (400 mag; scale bar ¼50 lm). (A–D)
and (E–H) depict two different animals, respectively. [Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
FIGURE 5. Masson’s Trichrome Staining of 4-week POCf implanted tissue specimens: (A,F) are histological staining of tissue samples taken
from the dorsal area of unmanipulated, control nude rats, (B,G) are POCf implanted animals, while (C,H) represent HBPOCf implanted ﬁlms. (D,I)
demonstrate an increase in blood vessel formation with the addition of the POCf-VEGF construct, while the greatest difference in vascularization
is seen in (E,J) containing the HBPOCf-VEGF constructs. Vessels are indicated by green arrows. Note the difference in vessel size from the
HBPOCf-VEGF to the POCf alone (400 mag; scale bar ¼50 lm). (A–E) and (F–J) depict two different animals, respectively. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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to be used for a variety of urological applications using cells
and either synthetic or biological-based scaffolds.5,14,26,27 If
one were to simplistically break down the components of
the bladder, it would include the urothelium that lines that
interior of the bladder allowing for a urine tight barrier; the
musculature that allows for repeated contraction/expansion
cycles; neural conduits; and a vascular supply. Apparent
pathogenic and nonpathogenic sources of cells have been
used to create the urothelial and muscle components of the
bladder with varying degrees of success.5,14 Severely lacking
in these models are schemes to create functional neural
components and highly interconnected networks of robust
vascularization. The ability to provide a foundation in which
adequate vascularization encompasses all aspects of the
regenerating bladder would be invaluable. This study was
performed as a proof of concept to demonstrate that the
chemical alteration of POC could provide a basis for
directed angiogenesis in vivo.
Previous studies using MSC seeded POCfs composites
demonstrated that these composites could function as sur-
rogate bladder tissue in a partial bladder cystectomy
model.14 Data from this study demonstrated that both
seeded and unseeded POCfs were impermeable to urine at
the onset of the study and provided this barrier until native
urothelium invaded and grew into the graft.14 Although the
study provided convincing evidence that bladder regenera-
tion took place using MSC/POC scaffolds, we postulated that
regeneration may be greatly enhanced with the localized
deposition of growth factors known to promote angiogene-
sis and smooth muscle development.12 This was based on
the observation that areas of regeneration were not as
highly vascularized as neighboring native tissue. Second,
bladder regeneration strategies often employ the use of
omentum to cover a newly transplanted bladder to provide
a potential source of vascularization to the newly implanted
bladder tissue.4 Within this scenario, the omentum is left in
place over the lifetime of the graft. Although this may act as
a means for vascular supply, the long-term effects of omen-
tum intermingling with bladder tissue have not been thor-
oughly evaluated. The omentum produces a wide variety of
hormones and growth factors that may be detrimental to
the regenerative process including proinﬂammatory cyto-
kines and chemokines.28 To avoid the future use of omen-
tum, POC was modiﬁed to release growth factors that could
possibly aid in the vascularization process. Initial in vitro
testing and subsequent growth factor release data from this
study demonstrated unique differences in the release pro-
ﬁles of the three growth factors examined. The three POCf
constructs provided evidence of sustained growth factor
release over time in which the POCf-IGF-1 construct showed
the highest levels of release (25.0 6 1.7 pg GF/mm2 POC).
This was signiﬁcantly greater than POCf-VEGF (4.7 6 0.9 pg
GF/ mm2 POC) and also greater than POCf-FGF2 (1.3 6 0.1
FIGURE 6. Immunoﬂuorescent imaging of POCf/cell tissues 4-weeks post augmentation. Antibodies against known endothelial cell markers
CD31 and vWF typically found in vasculature were used to identify blood vessels. (A) Represents unmanipulated control animal tissue stained
with CD31/FITC antibody (green). (B) POCf implanted tissue composite stained with CD31/FITC antibody. (C) HBPOCf implanted tissue composite
stained with CD31/FITC antibody. (D) POCf-VEGF implanted tissue composite stained with CD31/FITC antibody. (E) HBPOCf-VEGF implanted tis-
sue composite stained with CD31/FITC antibody. (F) Unmanipulated control animal tissue stained with vWF/FITC (green). (G) POCf implanted tis-
sue composite stained with vWF-FITC antibody. (H) HBPOCf implanted tissue composite stained with vWF-FITC. (I): POCf-VEGF implanted tissue
composite stained with vWF-FITC antibody. (J) HBPOCf-VEGF implanted tissue composite stained with vWF-FITC antibody. White arrows indi-
cate vasculature. All samples counter stained with DAPI (blue) to identify cell nuclei (400 mag; scale bar ¼ 50 lm). [Color ﬁgure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 7. In vivo vasculature quantiﬁcation analyses. HBPOCf-VEGF
implants produced a signiﬁcantly greater vascular response than
POCf, HBPOCf, or POCf-VEGF implants. Data shown as number of
vessels per mm2 represent mean 6 95% conﬁdence intervals for 12
ﬁelds surveyed per implant (n ¼ 10–11 implants per condition) (*p <
0.01; **p < 0.0001). [Color ﬁgure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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pg GF/ mm2 POC) at all time points at 30 days. At 30 days,
release amounts were 87.0 6 3.1 (pg GF/mm2 POC)
HBPOCf-IGF-1 versus 12.9 6 1.8 (pg GF/mm2 POC)
HBPOCf-VEGF versus 4.8 6 0.6 (pg GF/mm2 POC) HBPOCf-
IGF-1. The bulk release of growth factors with these POCf
constructs occurred by days 5–6 where 75% of VEGF and
IGF-1 were released and 50% of FGF2. In stark contrast,
growth factors bound to HBPOCfs required 9 days of incu-
bation before 75% of the growth factor was released with a
burst release of 50% of the growth factors released by
day 4. Since heparan sulfate is a highly sulfated glycosami-
noglycan, it may have provided a protective effect to bound
growth factors that allowed for their extended in vitro
release as many of these growth factors have a very short
half-life.29,30
The release proﬁles of these molecules appear quite dis-
parate and may be dependent upon several factors includ-
ing the number of heparan binding motifs contained within
each molecule as well as their respective molecular masses.
In the aforementioned data, IGF-1 consistently demonstrated
the highest level of release in both types of POCf constructs.
The predicted molecular mass for IGF-1 is 7.5 kDa, while
VEGF and FGF2 are 19.2 and 17.4 kDa, respectively.31–33
The reduced molecular mass of IGF-1 as compared with
VEGF and FGF2 may allow for higher numbers of IGF-1 mol-
ecules to occupy any given space hence the higher level of
release. The study of these particular three growth factors
in vitro was to demonstrate that the HBPOCfs possessed the
capability to bind and release three different classes of
proangiogenic growth factors. Secondary factors that may
have affected the differences in release proﬁles can be
attributed to the surface charge of the differing POCfs as
well as the shape and texturing of the POCfs as was demon-
strated by AFM data.
Materials that are used to act as scaffolds for tissue en-
gineering purposes come in many different embodiments.
One parameter of synthetically produced scaffolds that has
been recently shown to effect cellular growth is the surface
topography.34 Different methods have been used to speciﬁ-
cally create surfaces with texture, roughness, or patterns in
order for cells to receive cues to perform particular func-
tions.35,36 It has been further demonstrated that rougher
surfaces tend to foster cell growth and enhance adhesions
between cells and material, particularly in a urological set-
ting.37 This may be in part due to the notion that biomate-
rial surfaces have comparable dimensional qualities to pro-
teins that inherently stud cell surfaces, for example. This is
in contrast to material surfaces that are less rough or lack-
ing this aspect completely. AFM data presented within this
study demonstrate that POCf and HBPOCf displayed similar
average roughness values, while HBPOCf-VEGF constructs
contained a higher average roughness value and broader
surface distance with the presence of numerous hills and
valleys motifs as demonstrated in Figure 2(C). In vivo vessel
quantiﬁcation data of implanted scaffolds demonstrate that
the new vessel growth occurred at its highest levels in the
presence of the HBPOCf-VEGF that also expressed the high-
est degree of surface roughness. Data indicate that HBPOCf-
VEGF displayed an approximate fourfold and twofold
increase in vessel number compared with POCf and POCf-
VEGF, respectively. We speculate that the combination of
heparan bound growth factor and roughness allowed for
superior vascular growth as compared with the more ‘‘slick’’
surfaces found in the POCf and POCf-VEGF constructs. Cells
from the local subcutaneous environment may have been
recruited by growth factor signals and were able to
encroach and populate the HBPOCf-VEGF construct at multi-
ple depths/heights, forming close knit three-dimensional
cellular niches that may have been conducive to vascular
growth. However, one must take into account scalability
with regard to roughness. Objects that appear to be smooth
in appearance at one particular scale may indeed be tex-
tured at a smaller scale. An examination into the degree of
surface texture at various scales needs to be further investi-
gated as to eventually synthesize a scaffold with a textured
surface that is highly conducive to cell growth and
development.
The distribution of newly generated blood vessels in
HBPOCf-VEGF constructs appeared to be situated in certain
areas of the graft. Figure 4(C,F) displays areas of localized
angiogenesis that are demarcated by the black arrows. It is
evident in Figure 4(C) that the blood vessels are concen-
trated in a speciﬁc region of the HBPOCf-VEGF as the out-
line of the circumference of the HBPOCf-VEGF can be visual-
ized. This may be due to several reasons including a
localized concentration of VEGF as well as the duration in
which the graft was left in place. The chemistry involved in
the conjugation of the PEG spacer arm to the POCf would
indicate a 1:1 addition of PEG to free carboxylic acid groups
found on the POCfs. Although every effort was used to
evenly distribute the GFs onto the HBPOCf, alternative
methods may be employed in the future to ensure a better
so that optimal results may be achieved when ﬁlms are
placed in an in vivo tissue regenerative environment. Finally,
the in vivo environment and the length of time in which the
grafts remained also play a key role in the level of angiogen-
esis. Vessel formation may have become more homogenous
in distribution over time lending to a more robust level of
regeneration. Aside from these points, the data obtained
from this study clearly demonstrate increased angiogenesis
in HBPOCfs-VEGF as compared with controls at the gross,
microscopic, and quantitative levels.
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